Soligenix Inc (SNGX)

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine PR Newswire PRINCETON, N.J., June 8, 2026 Thermostability...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo PR Newswire...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results PR Newswire PRINCETON, N.J...

SNGX Phase 3 Trial Halted — HyBryte Setback Puts Strategy in Question

Soligenix halts its late-stage CTCL trial for futility, forcing a reassessment of its lead drug and future direction. Soligenix (NASDAQ:SNGX...